Program
tinengotinib
Also written as “TT-00420”, “TT-00420 (tinengotinib)” and “tinengotinib 10 mg QD plus darolutamide”.
Its studies are mostly in Cholangiocarcinoma · Prostatic Neoplasms · Breast Neoplasms · Carcinoma, Hepatocellular · Triple Negative Breast Neoplasms, led by 2 companies.
Drug pageTinengotinib: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TransThera Sciences (Nanjing)its history only | 105 open or running | phase 3since Jun 29, 2023 | Aug 21, 2018 | Dec 2026phase 3 · NCT05948475 |
| Akeso | 11 open or running | phase 2since Jun 26, 2025 | Jun 26, 2025 | May 10, 2027phase 2 · NCT07052253 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Akeso only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 25, 2022Named tinengotinibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TT-00420
- Jun 26, 2025First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT07052253 · 100 planned · China
Ahead
- May 10, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07052253
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Akeso leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07052253Carcinoma, Hepatocellular · China | 2 | Recruiting | May 10, 2027 | 100 |
How it is read
Names in the registry
- “TT-00420”, 4 entries
- “TT-00420 (tinengotinib)”, 3 entries
- “tinengotinib 10 mg QD plus darolutamide”, 1 entry
- “tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide”, 1 entry
- “tinengotinib 10 mg QD plus enzalutamide”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 6 studies
- Prostatic Neoplasms, 1 study
- Breast Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.